Financial Results Presentation for the First Half of the Fiscal Year Ending September 2026 | Amvis Holdings,Inc. (7071) timely disclosure

Worth reading

76Important

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

7.5

Year-on-year change in revenue (%)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial results presentationSecond quarter of the fiscal year ending September 202611 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥25,600 million+7.5%

Operating profit¥2,804 million-25.1%

Net income¥1,896 million-29.5%

Operating profit margin

Rate11

Year-on-year change (points)-4.7

Results for the three months of the current quarter

Net Sales

¥12,664 million

EBITDA

¥2,044 million

Operating profit

¥1,206 million

Net income

¥814 million

Full-year earnings forecast

Net Sales

¥51,700 million

EBITDA

¥7,100 million

Operating profit

¥3,800 million

Net income

¥2,100 million

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Net Sales49.5

EBITDA62.6

Operating profit73.8

Net income90.3

Ishinkan (medical care housing) business revenue49.2

Ishinkan (medical care housing) business EBITDA63.3

Ishinkan (medical care housing) business segment profit77.5

Comprehensive Medical Support Business revenue67

Comprehensive Medical Support Business operating profit before provisions67.7

Comprehensive Medical Support Business segment profit54.2

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

On track

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Change in revenue from existing facilities-569

Increase in personnel expenses at existing facilities (cost of sales)-328

Revenue increase from new facilities1,983

Increase in personnel expenses at new facilities (cost of sales)-1,274

Increase in land rents and rent expenses (cost of sales)-60

Increase in personnel expenses (SG&A)-118

Other-209

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Assumed decline in reimbursement rates due to the medical fee revisionApproximately 20%

Full-year number of new Ishinkan (medical care housing) facilities opened9

New medical institutions supported by the Comprehensive Medical Support Businessseveral hundred beds

New initiatives

The Comprehensive Medical Support Business will become an independent segment from the current fiscal year
Optimize staffing in preparation for the medical fee revision
Change to an opening strategy that prioritizes dominant regions and sites adjacent to supported medical institutions
Use a range of facility-opening schemes, including leases, M&A, real estate securitization and contracted real estate development
Introduce a record-checking function using IT tools
Introduce the internal communication tool TUNAG

Key KPIsA metric the company considers important as a management benchmark.

EBITDA

¥4,444 million-11.5%

EBITDA margin

17.4 %

yoy_change_point-3.7

Occupancy rate at existing facilities

74.2 %

Occupancy rate at new facilities

40 %

Percentage of end-of-life care provided in facilities

98.9 %

Average customer satisfaction

8.8 out of 10

NPS

57.1 Points

Unit price and quantity metricsThese figures show sales broken down by price and volume.

Length of stay for terminal cancer patients

The Company26 days

Palliative care wards27.9 days

Monthly admissions

1,000 people

Segment results

Ishinkan (medical care housing) business

Net Sales

¥25,033 million+6.1%

EBITDA

¥4,113 million-16.9%

Segment profit

¥2,479 million-32.5%

Comprehensive Medical Support Business

Net Sales

¥569 million

yoy2.5x

Operating profit before provisions

¥406 million

yoy3x

Segment profit

¥324 million

yoy5x

Financial targets

Target equity ratio30 %

Forecast equity ratio for the fiscal year ending September 2026well above 30%

Market Size / Share

Ishinkan (medical care housing) admissions as a percentage of cancer deaths in Japanapproximately 2.1%

Target marketapproximately 1.5 million hospital beds in Japan

Number of stores and locations

Number of facilities at period end135

Period-end capacity6,980

Facilities opened during the period6

Planned full-year number of facilities138

Planned full-year capacity7,178

Annual Dividend

Annual dividend per share¥4

End of period¥4

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Second quarter of the fiscal year ending September 2026
Net Sales	¥25,600 million (YoY +7.5%)
Operating profit	¥2,804 million (YoY -25.1%)
Net income	¥1,896 million (YoY -29.5%)
Operating profit margin	Rate 11 / Year-on-year change (points) -4.7
Results for the three months of the current quarter	Net Sales ¥12,664 million / EBITDA ¥2,044 million / Operating profit ¥1,206 million / Net income ¥814 million
Full-year earnings forecast	Net Sales ¥51,700 million / EBITDA ¥7,100 million / Operating profit ¥3,800 million / Net income ¥2,100 million
Progress against full-year forecast	Net Sales 49.5 / EBITDA 62.6 / Operating profit 73.8 / Net income 90.3 / Ishinkan (medical care housing) business revenue 49.2 / Ishinkan (medical care housing) business EBITDA 63.3 / Ishinkan (medical care housing) business segment profit 77.5 / Comprehensive Medical Support Business revenue 67 / Comprehensive Medical Support Business operating profit before provisions 67.7 / Comprehensive Medical Support Business segment profit 54.2
Self-assessment against the plan	On track
Segment results	Ishinkan (medical care housing) business Net Sales ¥25,033 million (YoY +6.1%) / EBITDA ¥4,113 million (YoY -16.9%) / Segment profit ¥2,479 million (YoY -32.5%) / Comprehensive Medical Support Business Net Sales ¥569 million / Operating profit before provisions ¥406 million / Segment profit ¥324 million
Breakdown of Factors Affecting the Change	Change in revenue from existing facilities -569 / Increase in personnel expenses at existing facilities (cost of sales) -328 / Revenue increase from new facilities 1,983 / Increase in personnel expenses at new facilities (cost of sales) -1,274 / Increase in land rents and rent expenses (cost of sales) -60 / Increase in personnel expenses (SG&A) -118 / Other -209
Key KPIs	EBITDA ¥4,444 million (YoY -11.5%) / EBITDA margin 17.4 % / Occupancy rate at existing facilities 74.2 % / Occupancy rate at new facilities 40 % / Percentage of end-of-life care provided in facilities 98.9 % / Average customer satisfaction 8.8 out of 10 / NPS 57.1 Points
Unit price and quantity metrics	Length of stay for terminal cancer patients The Company 26 days / Palliative care wards 27.9 days / Monthly admissions 1,000 people
Number of stores and locations	Number of facilities at period end 135 / Period-end capacity 6,980 / Facilities opened during the period 6 / Planned full-year number of facilities 138 / Planned full-year capacity 7,178
Assumptions Underlying the Business Outlook	Assumed decline in reimbursement rates due to the medical fee revision Approximately 20% / Full-year number of new Ishinkan (medical care housing) facilities opened 9 / New medical institutions supported by the Comprehensive Medical Support Business several hundred beds
Financial targets	Target equity ratio 30 % / Forecast equity ratio for the fiscal year ending September 2026 well above 30%
Annual Dividend	Annual dividend per share ¥4 / Interim Not disclosed / End of period ¥4
Market Size / Share	Ishinkan (medical care housing) admissions as a percentage of cancer deaths in Japan approximately 2.1% / Target market approximately 1.5 million hospital beds in Japan
New initiatives	The Comprehensive Medical Support Business will become an independent segment from the current fiscal year, Optimize staffing in preparation for the medical fee revision, Change to an opening strategy that prioritizes dominant regions and sites adjacent to supported medical institutions, Use a range of facility-opening schemes, including leases, M&A, real estate securitization and contracted real estate development, Introduce a record-checking function using IT tools, Introduce the internal communication tool TUNAG

Items this document does not state (11)

Ordinary incomeGross Profit MarginSelling, general and administrative expensesNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased following the opening and ramp-up of new facilities, while the factors cited for the decline included a temporary decrease in facility occupancy, higher personnel expenses resulting from shift changes, and the impact of the medical fee revision. The full-year forecast was left unchanged due to uncertainty regarding the impact of the medical fee revision.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.